Pneumococcal 15-valent conjugate vaccine - Biologic Drug Details

Summary for pneumococcal 15-valent conjugate vaccine

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for pneumococcal 15-valent conjugate vaccine

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Pneumococcal Vaccine
Chemical Structure	Pneumococcal Vaccines Vaccines, Conjugate Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pneumococcal 15-valent conjugate vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pneumococcal 15-valent conjugate vaccine Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	VAXNEUVANCE	pneumococcal 15-valent conjugate vaccine	Injection	125741	10,124,040	2035-08-21	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	VAXNEUVANCE	pneumococcal 15-valent conjugate vaccine	Injection	125741	10,967,060	2038-07-10	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	VAXNEUVANCE	pneumococcal 15-valent conjugate vaccine	Injection	125741	11,013,778	2037-02-22	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for pneumococcal 15-valent conjugate vaccine Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for pneumococcal 15-valent conjugate vaccine

Country	Patent Number	Estimated Expiration
European Patent Office	3718583
European Patent Office	2983744
Spain	2804598

Market Dynamics and Financial Trajectory for Pneumococcal 15-Valent Conjugate Vaccine

Last updated: February 20, 2026

What Are the Current Market Conditions for Pneumococcal 15-Valent Conjugate Vaccine?

The pneumococcal 15-valent conjugate vaccine (Vaxneuvance by Merck), approved by the FDA in July 2021, targets 15 serotypes of Streptococcus pneumoniae. It addresses gaps in coverage of existing vaccines, offering protection against additional serotypes responsible for invasive pneumococcal diseases (IPD).

Market size estimates for pneumococcal vaccines reach approximately $6.5 billion globally in 2022. Expectations project a compound annual growth rate (CAGR) of 8% through 2030, driven by expanding immunization programs and rising awareness of pneumococcal disease.

The rollout varies by region:

• North America: High adoption, driven by pediatric and adult vaccination programs.
• Europe: Moderate uptake, with some countries slow due to reimbursement hurdles.
• Asia-Pacific: Rapid growth potential, especially in China and India, due to expanding healthcare access.

The vaccine's formulation with 15 serotypes positions it among multivalent conjugates such as Prevnar 13 and Synflorix, with competition based on spectrum coverage and pricing strategies.

How Do Market Drivers Influence Financial Performance?

Rising Disease Burden and Immunization Policies

Global pneumococcal disease causes over 1 million deaths annually, primarily affecting children under five and elderly adults.[1] Governments increasingly include pneumococcal vaccines in national immunization programs, expanding market access.

Strengthening Pediatric and Adult Vaccination Programs

In developed countries, pediatric vaccination coverage exceeds 90%, promoting steady demand. Adult vaccination campaigns, especially among immunocompromised populations, further boost market potential.

Introduction of Higher-Valent Vaccines

The 15-valent vaccine offers broader serotype coverage than 13-valent vaccines, addressing serotype replacement concerns. This competitive edge may enable premium pricing and volume growth.

Pricing and Reimbursement Trends

Reimbursement variability impacts revenue; countries with national immunization programs tend to secure favorable tariffs. Value-based pricing models are emerging, aligning costs with health outcomes.

What Are the Financial Projections and Revenue Opportunities?

• Revenue Estimates

  • 2022: $400 million globally.
  • 2023-2030 CAGR: 8-10%, reaching approximately $1.2 billion by 2030.

• Market Segments

  • Pediatric use (~70% of sales).
  • Adult immunization (~30% of sales), with potential for growth as awareness increases.

• Regional Revenue Composition

  Region	2022 Revenue ($ millions)	Growth Potential
  North America	160	High, driven by mandates
  Europe	100	Moderate, reimbursement
  Asia-Pacific	60	Rapid growth expected
  Others	80	Emerging markets

• Pricing Strategy

  Average price per dose ranges from $30 to $50, depending on region and procurement channels.

What Are the Key Challenges and Risks?

• Market Penetration

  Competition from existing 13-valent vaccines, which dominate the market, reduces initial adoption.

• Reimbursement and Pricing Pressures

  Budget constraints and health authority negotiations may limit revenue growth in some markets.

• Serotype Replacement

  Evolving epidemiology could affect vaccine efficacy, necessitating continual reformulation.

• Manufacturing and Supply Chain

  Complex conjugation techniques pose production risks, with potential impacts on supply stability.

How Will Competitive Landscape Affect Future Revenue?

Multiple vaccine producers target pneumococcal disease. Notable competitors include:

• Pfizer (Prevnar 13)
• GlaxoSmithKline (Synflorix)
• Serum Institute of India (Pneumosil)

Emerging players and biosimilar entrants could pressure pricing and margins. Innovations such as protein-based or mRNA vaccines may reshape competition.

What Are the Strategic Implications for Stakeholders?

• Developers should focus on demonstrating broader serotype coverage and health economic benefits.
• Investors should monitor regional reimbursement policies and market access evolution.
• Healthcare providers need to adapt immunization schedules to include newer formulations.

Key Takeaways

• Market size for pneumococcal 15-valent conjugate vaccine projected to reach $1.2 billion by 2030.
• Growth driven by expanded immunization programs, broader serotype coverage, and regional adoption.
• Competition from established vaccines and reimbursement complexities pose challenges.
• Pricing ranges between $30-$50 per dose, with regional variability influencing revenue.
• Strategic success depends on market penetration, reformulation agility, and stakeholder engagement.

Frequently Asked Questions

1. How does the 15-valent vaccine differ from previous pneumococcal vaccines?
It includes 15 serotypes compared to 13 in Prevnar 13, offering protection against additional disease-causing strains.

2. What are the primary markets for the vaccine?
The United States, Europe, and rapidly developing Asia-Pacific countries are key markets.

3. What factors influence pricing strategies?
Reimbursement policies, disease burden, competition, and procurement volume govern pricing decisions.

4. What is the timeline for market growth?
Global demand is expected to grow at a CAGR of 8-10% from 2022 through 2030.

5. What risks could hinder market growth?
Serotype replacement, manufacturing challenges, and reimbursement delays may limit growth opportunities.

---

References

[1] World Health Organization. (2022). Pneumococcal disease. Retrieved from https://www.who.int

[2] GlobalData. (2023). Pneumococcal conjugate vaccines market. Market Insights Report.

[3] CDC. (2021). Pneumococcal Vaccination Recommendations. Retrieved from https://www.cdc.gov